Serum Institute of India, the flagship company of Poonawalla Group and India’s largest vaccine company, has acquired Bilthoven Biologicals of Netherlands. Through the acquisition, Serum Institute will get access to technology and expertise for making the Injectable Polio Vaccine (Salk).
This first overseas acquisition by the Poonawalla Group will also provide the Group and Serum Institute, an important manufacturing base in Europe, with access to the important European and the US markets.
Dr Cyrus Poonawalla, Chairman, Poonawalla Group and Serum Institute said, “The Poonawalla Group has constantly striven hard to provide the highest quality vaccines at affordable prices to the world. This acquisition will significantly strengthen our position in the global vaccines market, while giving us access to the technology and production facility of Injectable Polio Vaccine (Salk), which is the only logical solution available to the world for the eradication of polio. This will also significantly enhance our earlier offerings in the pediatric vaccines segment including DPT, Measles and MMR vaccines where we are the global leaders today.”
Adar Poonawalla, Executive Director, Poonawalla Group and Serum Institute said, “The Poonawalla Group is committed to investing over euros 70 – 80 million over the next three years to augment the infrastructure and enhance the manufacturing capacity of the Bilthoven’s facilities. Serum Institute has one of the world’s largest vaccine manufacturing facilities in Pune and with this second manufacturing facility based in Europe, the company aims to access the developed markets of Europe and US for its existing and future products in the pipeline.”
EP News Bureau – Mumbai
